312 related articles for article (PubMed ID: 23831221)
1. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
[TBL] [Abstract][Full Text] [Related]
2. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
Williams RD; Novack GD; van Haarlem T; Kopczynski C;
Am J Ophthalmol; 2011 Nov; 152(5):834-41.e1. PubMed ID: 21794845
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
JAMA Ophthalmol; 2013 Oct; 131(10):1288-95. PubMed ID: 23787820
[TBL] [Abstract][Full Text] [Related]
4. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
[TBL] [Abstract][Full Text] [Related]
5. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
[TBL] [Abstract][Full Text] [Related]
6. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy.
Goldberg I; Crowston JG; Jasek MC; Stewart JA; Stewart WC;
J Glaucoma; 2012 Jan; 21(1):55-9. PubMed ID: 21048504
[TBL] [Abstract][Full Text] [Related]
7. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
8. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
Hatanaka M; Reis A; Sano ME; Susanna R
J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
[TBL] [Abstract][Full Text] [Related]
9. Duration of IOP reduction with travoprost BAK-free solution.
Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
[TBL] [Abstract][Full Text] [Related]
10. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
[TBL] [Abstract][Full Text] [Related]
11. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
12. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
[TBL] [Abstract][Full Text] [Related]
13. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
[TBL] [Abstract][Full Text] [Related]
16. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
Katz G; Dubiner H; Samples J; Vold S; Sall K
JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
[TBL] [Abstract][Full Text] [Related]
18. Ocular hypotensive efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
Cantor LB; WuDunn D; Cortes A; Hoop J; Knotts S
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S12-8. PubMed ID: 15016557
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy.
Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
J Glaucoma; 2017 Feb; 26(2):96-100. PubMed ID: 27661993
[TBL] [Abstract][Full Text] [Related]
20. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension.
Brandt JD; Cantor LB; Katz LJ; Batoosingh AL; Chou C; Bossowska I;
J Glaucoma; 2008; 17(3):211-6. PubMed ID: 18414107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
